Navigation Links
Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
Date:5/29/2009

NEW HAVEN, Conn., May 29 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

The poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Elderly de novo Poor Risk AML Patients Treated with Laromustine" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M4 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009. A copy of the poster will be available on Vion Pharmaceuticals' website, www.vionpharm.com, on May 30, 2009 at 8:00 a.m. Eastern Time.

In addition, the Company announced that additional data on Onrigin would be presented in a poster from an investigator-sponsored trial of Onrigin in combination with cytarabine in elderly patients with previously untreated AML. The trial is sponsored by the Weill-Cornell Medical College. The poster (Abstract #7054) entitled "Phase I Trial of Laromustine in Combination with Infusional Ara-C in Elderly Patients Over Age 60 with Newly Diagnosed AML or High-Grade MDS" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M10 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The Company has an NDA under review with the FDA fo
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
2. American Academy of Dermatology Recognizes Merz Pharmaceuticals
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
5. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
6. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
7. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
8. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
9. Agios Pharmaceuticals founders author Science review on cancer metabolism
10. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
11. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... than 40 years away from a food shortage that ... to a top scientist at the U.S. Agency for ... food production will be limited on a global scale ... Dr. Fred Davies, senior science advisor for the agency,s ... politically destabilizing by 2050 as energy issues are today.", ...
(Date:4/17/2014)... An anti-malarial treatment that lost its status as the ... a new lease of life, with new research indicating ... findings could revive the use of the cheap anti-malarial ... which claims the lives of more than half a ... parasite that causes malaria has developed resistance to chloroquine, ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2
... HealthDay Reporter , FRIDAY, Feb. 25 (HealthDay News) ... assistant for minor ailments when their family doctor can,t fit ... -- a dental therapist who could perform basic dental procedures ... invasive procedures, such as extractions and oral surgery. Not ...
... sophisticated imaging test to probe for higher-level cognitive functioning in ... the view it presents is one that is blurred in ... the Feb. 25 online edition of the journal Brain ... in their function from minimally conscious state to the locked-in ...
... THURSDAY, Feb. 24 (HealthDay News) -- While experts stress that ... past, isolated cases still appear, even in the United States. ... American lab worker died from plague in 2009 -- the ... and the first known death from a weakened form of ...
... recommended that men with a rapid rise in PSA have ... other indication and the PSA is within the "normal" range. ... poor predictor of prostate cancer, and may lead to many ... in the Journal of the National Cancer Institute. ...
... Gardner HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay ... removed a portion of the organ a day after birth, ... is renewed hope that ways can be found to help ... in a mammalian heart for regeneration, but they,re somehow permanently ...
... has long been associated with a reduced risk of breast ... a woman gives birth, the higher her risk of "triple-negative" ... the disease. Conversely, women who never give birth have a ... a poorer prognosis than other types of breast cancer and ...
Cached Medicine News:Health News:Special Assistants Making Inroads in Dentistry 2Health News:Special Assistants Making Inroads in Dentistry 3Health News:Brain imaging provides window into consciousness 2Health News:Brain imaging provides window into consciousness 3Health News:Brain imaging provides window into consciousness 4Health News:Brain imaging provides window into consciousness 5Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... FRANKLIN LAKES, N.J., April 13, 2011 BD (Becton, Dickinson ... it will conduct a live webcast of its second fiscal ... 10:00 – 11:00 a.m. (ET).  BD will issue a press ... Tuesday, April 26, 2011. The webcast of the ...
... HAVEN, Conn., April 13, 2011 Marinus Pharmaceuticals, Inc., ... nervous system disorders, today announced the award of a ... to study its lead candidate ganaxolone for the treatment ... by selective binding to the neurosteroid receptor. Early research ...
Cached Medicine Technology:Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
... Sierra Universal Collar fits the vast majority of ... motion restriction needed to protect your patients.,You can ... for the right fit . . . right ... design alleviate storage problems, the collar is available ...
Shoulder Immobilizer with Body Strap Navy blue cotton. Thumb look helps keep hand in neutral position. Padded, 2" blue pile material laminated to foam shoulder and body strap. Fits left or right. 5/p...
... orthosis is designed for the management ... diaphyseal fractures. The lightweight anatomical design ... compression for optimal control of humeral ... both shoulder and elbow joints. In ...
... pre-fabricated orthosis is designed for the ... humeral diaphyseal fractures. The lightweight anatomical ... tissue compression for optimal control of ... of both the shoulder and elbow ...
Medicine Products: